靶向PD-1、巨噬细胞浸润与IDO通路激活在肉瘤中的应用:一项2期临床试验
这项开放标签多中心2期研究评估了帕博利珠单抗联合节拍环磷酰胺在晚期软组织肉瘤和胃肠间质瘤中的疗效与安全性。57例患者入组,50例可评估疗效,仅1例孤立性纤维瘤达部分缓解,6个月无进展率在平滑肌肉瘤和未分化多形性肉瘤均为0%,其他肉瘤为14.3%,胃肠间质瘤为11.1%。作者认为PD-1抑制在所选软组织肉瘤和胃肠间质瘤中活性有限,可能与巨噬细胞浸润和IDO1通路激活导致的免疫抑制微环境有关。
要点
- 帕博利珠单抗联合节拍环磷酰胺在晚期软组织肉瘤和胃肠间质瘤中客观缓解率低。
- 6个月无进展率:平滑肌肉瘤0%、未分化多形性肉瘤0%、其他肉瘤14.3%、胃肠间质瘤11.1%。
- 多数病例可见表达IDO1的巨噬细胞强浸润,治疗期间血浆犬尿氨酸/色氨酸比值显著升高。
核心结论
- PD-1抑制在所选晚期软组织肉瘤和胃肠间质瘤中活性有限,可能由巨噬细胞浸润和IDO1通路激活所致的免疫抑制微环境解释。
研究设计与样本
- 开放标签、多中心2期研究,纳入晚期软组织肉瘤四个队列:平滑肌肉瘤、未分化多形性肉瘤、其他肉瘤和胃肠间质瘤。
- 所有患者接受环磷酰胺50 mg每日两次,用药1周停1周,联合帕博利珠单抗200 mg静脉给药每3周一次。
- 2015年6月至2016年7月共入组57例患者(中位年龄59.5岁,范围18.5-84.0岁;女性24例[42%]),其中50例可评估疗效终点。
主要发现
- 3例患者出现肿瘤缩小,仅1例孤立性纤维瘤达部分缓解。
- 6个月无进展率:平滑肌肉瘤0%、未分化多形性肉瘤0%、其他肉瘤14.3%(95% CI,1.8%-42.8%)、胃肠间质瘤11.1%(95% CI,2.8%-48.3%)。
- 最常见不良事件为1级或2级疲乏、腹泻和贫血。
- 唯一达部分缓解的患者也是唯一免疫细胞中程序性死亡配体1强阳性染色的患者。
- 多数病例可见表达抑制性酶吲哚胺2,3-双加氧酶1(IDO1)的巨噬细胞强浸润,且研究治疗期间患者血浆样本中犬尿氨酸/色氨酸比值显著升高。
关键数值与推荐
- 双主要终点包括平滑肌肉瘤、未分化多形性肉瘤和其他肉瘤按RECIST v1.1评估的6个月无进展和客观缓解,以及胃肠间质瘤的6个月无进展。
- 客观缓解率20%和/或6个月无进展率60%被确定为具有有意义疗效的合理目标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is a strong rationale for treating sarcomas with immunotherapy. OBJECTIVE: To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, multicenter, phase 2 study of 4 cohorts of patients with advanced soft-tissue sarcoma (STS), including leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), other sarcomas (others), and gastrointestinal stromal tumor (GIST). All patients received 50 mg twice daily cyclophosphamide 1 week on and 1 week off and 200 mg of intravenous pembrolizumab every 3 weeks. INTERVENTION OR EXPOSURE: Pembrolizumab in combination with metronomic cyclophosphamide. MAIN OUTCOMES AND MEASURES: There was a dual primary end point, encompassing both the nonprogression and objective responses at 6 months per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for LMS, UPS, and others and 6-month nonprogression for GIST. An objective response rate of 20% and/or a 6-month nonprogression rate of 60% were determined as reasonable objectives for treatment with meaningful effect. Correlative studies of immune biomarkers were planned from patient tumor and plasma samples. RESULTS: Between June 2015 and July 2016, 57 patients were included (median [range] age, 59.5 [18.5-84.0] years; 24 women [42%]); 50 patients were assessable for the efficacy end point. Three patients experienced tumor shrinkage, resulting in a partial response in a single solitary fibrous tumor. The 6-month nonprogression rates were 0%, 0%, 14.3% (95% CI, 1.8%-42.8%) for LMS, UPS, and others, respectively, and 11.1% (95% CI, 2.8%-48.3%) for GIST. The most frequent adverse events were grade 1 or 2 fatigue, diarrhea, and anemia. The only patient who experienced partial response was the only one with strong programmed cell death 1 ligand 1-positive staining in immune cell. Strong infiltration by macrophage expressing the inhibitory enzyme indoleamine 2,3-dioxygenase 1 (IDO1) was observed in the majority of cases. Moreover, a significant increase in the kynurenine to tryptophan ratio was observed in patient plasma samples during the study treatment. CONCLUSIONS AND RELEVANCE: We found that PD-1 inhibition has limited activity in selected STS and GIST. This may be explained by an immunosuppressive tumor microenvironment resulting from macrophage infiltration and IDO1 pathway activation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02406781.
引用
- Toulmonde M, Penel N, Adam J, et al. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. JAMA Oncol. 2018. PMID: 28662235. doi:10.1001/jamaoncol.2017.1617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。